Access here alternative investment news about Lupin's Goa Plant: Usfda Finds Certain Investigation, Material Testing Deficiencies

Lupin's Goa Plant: Usfda Finds Certain Investigation, Material Testing Deficiencies

by moneycontrol.com posted 3weeks ago 0 views
Lupin said the company is confident of addressing the observations satisfactorily. : Pre-configured baskets of stocks & ETFs that you can invest in with a single click. Developed by hedge funds, global asset management companies, experienced wealth management firms and portfolio managers. Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas Drugmaker Lupin's Goa oral solid formulation facility has received seven observations from US Food and Drug Administration (USFDA), which is mostly related to investigation of out-of-specification (OOS) drug productions and testing deficiencies of input materials, among others.

In this article

No tags related to this article.